Premium
A New Medical Device Rigeneracons Allows to Obtain Viable Micro‐Grafts From Mechanical Disaggregation of Human Tissues
Author(s) -
Trovato Letizia,
Monti Manuela,
del Fante Claudia,
Cervio Marila,
Lampinen Milla,
Ambrosio Lucia,
Redi Carlo Alberto,
Perotti Cesare,
Kankuri Esko,
Ambrosio Gennaro,
Rodriguez Y. Baena Ruggero,
Pirozzi Giuseppe,
Graziano Antonio
Publication year - 2015
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.24973
Subject(s) - viability assay , mesenchymal stem cell , periosteum , cell , biomedical engineering , regeneration (biology) , regenerative medicine , microbiology and biotechnology , biology , anatomy , pathology , stem cell , medicine , biochemistry
Autologous graft is considered the gold standard of graft materials; however, this approach is still limited due to both small amount of tissue that can be collected and to reduced cell viability of cells that can be obtained. The aim of this preliminary study was to demonstrate the efficacy of an innovative medical device called Rigeneracons® (CE certified Class I) to provide autologous micro‐grafts immediately available to be used in the clinical practice. Moreover, Rigeneracons® is an instrument able to create micro‐grafts enriched of progenitors cells which maintain their regenerative and differentiation potential. We reported preliminary data about viability cell of samples derived from different kind of human tissues, such as periosteum, cardiac atrial appendage biopsy, and lateral rectus muscle of eyeball and disaggregated by Rigeneracons®. In all cases we observed that micro‐grafts obtained by Rigeneracons® displayed high cell viability. Furthermore, by cell characterization of periosteum samples, we also evidenced an high positivity to mesenchymal cell markers, suggesting an optimal regenerative potential. J. Cell. Physiol. 230: 2299–2303, 2015. © 2015 Wiley Periodicals, Inc.